Company intelligence / Profile preview

V-Co 2

Ownership: Private
Development stage: Other

Overview

V-Co 2 is a biotechnology company focused on the development of next-generation vaccine candidates, specifically targeting infectious diseases such as COVID-19. The company's lead program is a vaccine candidate designed to provide robust and durable immune responses against various strains of the SARS-CoV-2 virus. V-Co 2 leverages advanced immunological research to optimize vaccine efficacy and safety profiles. The company is currently advancing its primary candidate through early-stage clinical trials to evaluate its potential as a primary or booster vaccination option. By focusing on innovative vaccine design, V-Co 2 aims to address ongoing global health challenges and improve pandemic preparedness.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Beyond the preview

Go deeper on V-Co 2.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-Co 2.

Explore the full profile